Review explores CAF subtypes influencing chemoresistance in ovarian cancer, suggesting new therapeutic strategies.
Key Points
This review aims to elucidate the heterogeneous roles of cancer-associated fibroblasts (CAFs) in ovarian cancer and their contribution to chemoresistance.
Synthesis of evidence from recent single-cell and proteomic analyses.
Delineation of CAF subtypes including myCAFs, iCAFs, and apCAFs.
Exploration of the relationship between CAF-mediated pathways and platinum-based chemoresistance.
High expression of CAF-associated genes correlates with platinum resistance in ovarian cancer.
VCAN enhances ECM stiffness and immune suppression; SULF1 alters ECM sulfation affecting drug uptake.
Targeting CAF subtypes may enhance treatment efficacy and improve patient outcomes.